Friends study: drugs that earn Breakthrough Therapy Designation at FDA provide maximum benefit in lung cancer

DOD Lung Cancer Research Program funding opportunities for FY24

The FY24 Defense Appropriations Act provides funding for the LCRP to support innovative, high-impact lung cancer research. The managing agent for the anticipated funding opportunities is the CDMRP at the U.S. Army Medical Research and Development Command.

April 12, 2024

Vol.50 No.15

Clinical Roundup

Imfinzi improves OS and PFS in limited-stage LS-SCLC in phase III trial

In the phase III ADRIATIC trial, Imfinzi (durvalumab) showed a statistically significant and clinically meaningful improvement in overall survival and progression-free survival for patients with limited-stage small cell lung cancer who had not progressed following concurrent chemoradiotherapy, compared to placebo after cCRT.

April 12, 2024

Vol.50 No.15

Drugs & Targets

FDA grants accelerated approval to Enhertu for unresectable or metastatic HER2-positive solid tumors

FDA granted accelerated approval to Enhertu (fam-trastuzumab deruxtecan-nxki) for adult patients with unresectable or metastatic HER2-positive (IHC3+) solid tumors who have received prior systemic treatment and have no satisfactory alternative treatment options.

April 12, 2024

Vol.50 No.15

White House

White House misses deadline to finalize FDA rule banning menthol cigarettes, prompting lawsuit from health groups

A coalition of health and physician groups earlier this week filed a lawsuit seeking to force FDA to finalize a long-delayed final rule banning menthol cigarettes.

Ellen Sigal, Marlene Malek, Scott LaGanga, Tim Lawrence to receive advocacy, philanthropy awards by Georgetown Lombardi

Ellen V. Sigal, Marlene A. Malek, Scott LaGanga, and Tim Lawrence will be honored at the 36th Annual Lombardi Gala, an annual event dedicated to raising funds for Georgetown University’s Lombardi Comprehensive Cancer Center.

April 05, 2024

Vol.50 No.14

Drugs & Targets

FDA approves Abecma for earlier lines of treatment for MM

FDA approved Abecma (idecabtagene vicleucel; ide-cel) for the treatment of adult patients with relapsed or refractory multiple myeloma after two or more prior lines of therapy including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 monoclonal antibody, based on results from the KarMMa-3 trial (The Cancer Letter, March 22, 2024).

April 05, 2024

Vol.50 No.14

Friends study: drugs that earn Breakthrough Therapy Designation at FDA provide maximum benefit in lung cancer

YOU MAY BE INTERESTED IN

DOD Lung Cancer Research Program funding opportunities for FY24

Imfinzi improves OS and PFS in limited-stage LS-SCLC in phase III trial

FDA grants accelerated approval to Enhertu for unresectable or metastatic HER2-positive solid tumors

White House misses deadline to finalize FDA rule banning menthol cigarettes, prompting lawsuit from health groups

Ellen Sigal, Marlene Malek, Scott LaGanga, Tim Lawrence to receive advocacy, philanthropy awards by Georgetown Lombardi

FDA approves Abecma for earlier lines of treatment for MM

Renew today!

Subscriber content

Login